Researchers at the University of Plymouth are leading an innovative initiative to advance the study of meningiomas in NF2-related schwannomatosis (NF2-SWN).

AbbVie announced positive topline results from its pivotal Phase III TEMPO-2 trial, evaluating tavapadon as a flexible-dose (5mg to 15mg, once daily) monotherapy in early Parkinson's disease (PD).

Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of ...

Vitamin D regulates hormones, reduces menstrual pain, supports fetal development and preserves bone health during menopause.

In an official announcement the Russian Health Ministry said that a cancer vaccine will be launched in 2025 and will be ...

Pfizer Inc. (NYSE:PFE) today provided its full-year 2025 guidance(1) and reaffirmed its October 29, 2024 full-year 2024 guidance(1) . The accompanying ...

AI Powered Blood Test Detects Earliest Stage of Breast Cancer: Study FindsA new screening method that combines laser analysis ...

Drug discovery& development includes several processes and phases that demand a huge amount of funds ... drug optimization and repurposing, preclinical and clinical testing, and others), and end-user ...

The global artificial intelligence in clinical trials market is forecasted to grow steadily from US$1.20 billion in 2023 to ...

Discover the latest advancements in small cell lung cancer through Novotech CRO’s in-depth disease analysis. Gain valuable insights into novel therapies, ongoing clinical trials, and future ...

Danforth Advisors, LLC, today announced the acquisition of VPMR, LLC, a full-service, global market research firm serving ...